Status and phase
Conditions
Treatments
About
The purpose of the study is to determine whether transarterial chemoembolization containing arsenic trioxide is safe and effective in the treatment of intermediate-stage hepatocellular carcinoma.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
Exclusion criteria
Primary purpose
Allocation
Interventional model
Masking
250 participants in 2 patient groups, including a placebo group
There are currently no registered sites for this trial.
Central trial contact
Haibo Shao, MD,PHD
Start date
Jan 01, 2014 • 11 years ago
End date
Dec 01, 2015 • 9 years ago
Today
Jan 22, 2025
Lead Sponsor
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal